B-intervention	0	9	Letrozole
O	10	12	in
O	13	21	advanced
O	22	28	breast
O	29	35	cancer
O	35	36	:
O	37	40	the
O	41	45	PO25
O	46	51	trial
O	51	52	.

O	53	62	Tamoxifen
O	63	66	has
O	67	71	been
O	72	73	a
O	74	82	standard
O	83	88	first
O	88	89	-
O	89	93	line
O	94	103	endocrine
O	104	111	therapy
O	112	115	for
O	116	120	post
O	120	121	-
O	121	131	menopausal
O	132	137	women
O	138	142	with
O	143	150	hormone
O	150	151	-
O	151	161	responsive
O	162	170	advanced
O	171	177	breast
O	178	184	cancer
O	184	185	,
O	186	189	but
O	190	194	more
O	195	199	than
O	200	204	half
O	205	207	of
O	208	216	patients
O	217	221	fail
O	222	224	to
O	225	232	respond
O	233	236	and
O	237	241	time
O	242	244	to
O	245	256	progression
O	257	259	is
O	260	264	less
O	265	269	than
O	270	272	12
O	273	279	months
O	280	282	in
O	283	293	responders
O	293	294	.

O	295	298	The
O	299	304	third
O	304	305	-
O	305	315	generation
O	316	325	aromatase
O	326	336	inhibitors
O	337	341	were
O	342	351	developed
O	352	354	to
O	355	362	provide
O	363	367	more
O	368	377	effective
O	378	390	alternatives
O	391	393	to
O	394	403	tamoxifen
O	403	404	.

O	405	407	In
O	408	411	the
O	412	418	Femara
O	419	424	Study
O	425	429	PO25
O	429	430	,
B-eligibility	431	435	post
I-eligibility	435	436	-
I-eligibility	436	446	menopausal
I-eligibility	447	452	women
I-eligibility	453	457	with
I-eligibility	458	466	advanced
I-eligibility	467	473	breast
I-eligibility	474	480	cancer
O	481	485	were
O	486	496	randomized
O	497	499	to
O	500	507	receive
O	508	517	letrozole
O	518	519	2
O	519	520	.
O	520	521	5
O	522	524	mg
O	525	526	(
O	526	527	n
O	527	528	=
B-intervention-participants	528	531	453
O	531	532	)
O	533	535	or
B-control	536	545	tamoxifen
O	546	548	20
O	549	551	mg
O	552	553	(
O	553	554	n
O	554	555	=
B-control-participants	555	558	454
O	558	559	)
O	560	565	given
O	566	572	orally
O	573	578	daily
O	579	584	until
O	585	596	progressive
O	597	604	disease
O	605	613	occurred
O	613	614	.

O	615	623	Patients
O	624	628	were
O	629	638	permitted
O	639	641	to
O	642	647	cross
O	648	652	over
O	653	655	to
O	656	659	the
O	660	665	other
O	666	675	treatment
O	676	678	at
O	679	690	progression
O	690	691	.

O	692	694	In
O	695	698	the
O	699	706	primary
O	707	715	efficacy
O	716	724	analysis
O	724	725	,
B-outcome	726	732	median
I-outcome	733	737	time
I-outcome	738	740	to
I-outcome	741	752	progression
I-outcome	753	754	(
I-outcome	754	757	TTP
I-outcome	757	758	)
O	759	762	was
O	763	776	significantly
O	777	783	longer
O	784	788	with
O	789	798	letrozole
O	799	803	than
O	804	808	with
O	809	818	tamoxifen
O	819	820	(
B-iv-cont-median	820	821	9
I-iv-cont-median	821	822	.
I-iv-cont-median	822	823	4
I-iv-cont-median	824	830	months
O	831	833	vs
O	833	834	.
B-cv-cont-median	835	836	6
I-cv-cont-median	836	837	.
I-cv-cont-median	837	838	0
I-cv-cont-median	839	845	months
O	845	846	,
O	847	859	respectively
O	859	860	;
O	861	862	P
O	862	863	<
O	863	864	0
O	864	865	.
O	865	869	0001
O	869	870	)
O	870	871	.

O	872	875	The
B-outcome	876	885	objective
I-outcome	886	894	response
I-outcome	895	899	rate
I-outcome	900	901	(
I-outcome	901	904	ORR
I-outcome	904	905	)
O	906	909	was
O	910	923	significantly
O	924	930	higher
O	931	934	for
O	935	944	letrozole
O	945	949	than
O	950	953	for
O	954	963	tamoxifen
O	964	965	(
B-iv-bin-percent	965	967	32
I-iv-bin-percent	967	968	%
O	969	971	vs
O	971	972	.
B-cv-bin-percent	973	975	21
I-cv-bin-percent	975	976	%
O	976	977	;
O	978	979	P
O	979	980	=
O	980	981	0
O	981	982	.
O	982	986	0002
O	986	987	)
O	987	988	.

O	989	1002	Prospectively
O	1003	1010	planned
O	1011	1019	analyses
O	1020	1022	of
O	1023	1026	the
O	1027	1033	intent
O	1033	1034	-
O	1034	1036	to
O	1036	1037	-
O	1037	1042	treat
O	1043	1053	population
O	1054	1060	showed
O	1061	1065	that
O	1066	1075	letrozole
O	1076	1089	significantly
O	1090	1098	improved
B-outcome	1099	1106	overall
I-outcome	1107	1115	survival
I-outcome	1116	1117	(
I-outcome	1117	1119	OS
I-outcome	1119	1120	)
O	1121	1129	compared
O	1130	1134	with
O	1135	1144	tamoxifen
O	1145	1149	over
O	1150	1153	the
O	1154	1159	first
O	1160	1162	24
O	1163	1169	months
O	1170	1172	of
O	1173	1176	the
O	1177	1182	trial
O	1182	1183	.

O	1184	1186	An
O	1187	1198	exploratory
O	1199	1207	analysis
O	1208	1210	of
O	1211	1219	patients
O	1219	1220	,
O	1221	1224	who
O	1225	1228	did
O	1229	1232	not
O	1233	1238	cross
O	1239	1243	over
O	1243	1244	,
O	1245	1254	indicated
O	1255	1256	a
B-outcome	1257	1263	median
I-outcome	1264	1266	OS
O	1267	1274	benefit
O	1275	1277	of
O	1278	1280	14
O	1281	1287	months
O	1288	1291	for
O	1292	1301	letrozole
O	1302	1310	compared
O	1311	1315	with
O	1316	1325	tamoxifen
O	1325	1326	.

O	1327	1336	Letrozole
O	1337	1339	is
O	1340	1343	the
O	1344	1348	only
O	1349	1354	third
O	1354	1355	-
O	1355	1365	generation
O	1366	1375	aromatase
O	1376	1385	inhibitor
O	1386	1390	that
O	1391	1394	has
O	1395	1407	demonstrated
O	1408	1419	significant
O	1420	1432	improvements
O	1433	1435	in
O	1436	1439	ORR
O	1439	1440	,
O	1441	1444	TTP
O	1444	1445	,
O	1446	1449	and
O	1450	1455	early
O	1456	1458	OS
O	1458	1459	.
